This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • HIV/AIDS  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Infliximab is a monoclonal anti–tumor necrosis factor (TNF)- antibody indicated in steroid-resistant and/or fistulizing Crohn disease (CD). Reactivation of chronic viral hepatitis as well as opportunistic infections have been reported as adverse effects,^1-2 but the impact of such drugs on patients' virological and immunological status remains unknown.³

We report the case of a 35-year-old woman hospitalized in 2003 for a flare-up of colonic CD diagnosed in 1988. Treatment with azathioprine started in 1995 resulted in clinical remission until early 2001, when multiple superficial lymph nodes appeared. Human immunodeficiency virus (HIV) primary infection was confirmed, and antiretroviral therapy was prescribed for 1 year, allowing undetectable viral load. A new CD relapse in mid-2002 was treated with budesonide, inducing clinical remission. In late 2002, the patient was hospitalized for another luminal flare-up, with a high CD activity index of 341). Findings from a colonoscopy showed scattered lesions extending from the rectum up . . . [Full Text of this Article]

AUTHOR INFORMATION
Jérôme Filippi, MD; Pierre-Marie Roger, MD, PhD; Stéphane M. Schneider, MD; Jacques Durant, MD; Jean-Philippe Breittmayer, PhD; Sylvia Benzaken, MD; Alain Bernard, MD, PhD; Pierre Dellamonica, MD, PhD; Xavier Hébuterne, MD, PhD for the Groupe d’Etude Niçois Polyvalent en Infectiologie(GENPI)